Global Ingredient Risk Index Probiotics

Pediococcus acidilactici

Pediococcus acidilactici

Also known as: Pediococcus acidilactici R1001, P. acidilactici

27 მარ 2026

LOW RISK 1.5/10 How?

This ingredient is classified as unclassified risk.

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

Pediococcus acidilactici is a lactic acid bacterium used as a probiotic for immune modulation and GI health. It has a good safety record. Some strains carry intrinsic vancomycin resistance (a chromosomal trait, not transferable); this is not considered a safety concern for supplemental use. Standard probiotic caution applies for immunocompromised individuals.

Scientific Name: Pediococcus acidilactici

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Probiotics

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Probiotics

Ingredient Pediococcus acidilactici

Scientific name Pediococcus acidilactici

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Probiotics
Evidence consistency: High consistency across studies (100%)

Safety Signals

No significant safety signals identified in the reviewed literature.

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for Pediococcus acidilactici indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Pediococcus acidilactici

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name Pediococcus acidilactici

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 06 აპრ 2026, 12:11

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Pediococcus acidilactici WSP-AZM23: Genomic Insights, In Vitro Probiotic Potential, and Computational Analysis for Biotherapeutic Applications. ↗

PMID 41931223 ↗

Journal Biochem Genet

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41931223/

Akmaliyah R et al.. Pediococcus acidilactici WSP-AZM23: Genomic Insights, In Vitro Probiotic Potential, and Computational Analysis for Biotherapeutic Applications.. Biochem Genet. 2026. PMID:41931223.
Observational / other LOW evidence YELLOW
Host intestinal microbiota adaptive changes following Paranosema locustae infection and mechanism of chronic pathogenesis. ↗

PMID 41911519 ↗

Journal J Insect Sci

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41911519/

Zhang H et al.. Host intestinal microbiota adaptive changes following Paranosema locustae infection and mechanism of chronic pathogenesis.. J Insect Sci. 2026. PMID:41911519.
Observational / other LOW evidence YELLOW
Enhanced flavor and biogenic amine safety of salt-reduced Doubanjiang through co-inoculated fermentation with Pediococcus acidilactici and Zygosaccharomyces rouxii. ↗

PMID 41895950 ↗

Journal Food Res Int

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41895950/

Liao S et al.. Enhanced flavor and biogenic amine safety of salt-reduced Doubanjiang through co-inoculated fermentation with Pediococcus acidilactici and Zygosaccharomyces rouxii.. Food Res Int. 2026. PMID:41895950.
Observational / other LOW evidence YELLOW
Feruloyl esterase-producing lactobacillus screening and its synergistic effect with homolactic and heterolactic bacteria on corn stover silage. ↗

PMID 41868373 ↗

Journal Front Microbiol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41868373/

Wang L et al.. Feruloyl esterase-producing lactobacillus screening and its synergistic effect with homolactic and heterolactic bacteria on corn stover silage.. Front Microbiol. 2026. PMID:41868373.
Observational / other LOW evidence YELLOW
Cellulosic L-Lactic Acid Production by Engineered Na(+)-Tolerant Pediococcus acidilactici and Bipolar Membrane Electrodialysis Purification for L-Lactide Synthesis. ↗

PMID 41863517 ↗

Journal Biotechnol Bioeng

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41863517/

Li Z et al.. Cellulosic L-Lactic Acid Production by Engineered Na(+)-Tolerant Pediococcus acidilactici and Bipolar Membrane Electrodialysis Purification for L-Lactide Synthesis.. Biotechnol Bioeng. 2026. PMID:41863517.
Observational / other LOW evidence YELLOW
Lactobacillus acidophilus combined with Pediococcus acidilactici ameliorates colitis. ↗

PMID 41859447 ↗

Journal Front Microbiol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41859447/

Yu P et al.. Lactobacillus acidophilus combined with Pediococcus acidilactici ameliorates colitis.. Front Microbiol. 2026. PMID:41859447.
Observational / other LOW evidence YELLOW
Phytosynbiotic Containing Double-Layer Microencapsulated Pediococcus acidilactici V202 and Tiliacora triandra Leaf Extract Improve Growth Performance and Gut Health in Broiler Chickens. ↗

PMID 41829053 ↗

Journal Animals (Basel)

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41829053/

Nopparatmaitree M et al.. Phytosynbiotic Containing Double-Layer Microencapsulated Pediococcus acidilactici V202 and Tiliacora triandra Leaf Extract Improve Growth Performance and Gut Health in Broiler Chickens.. Animals (Basel). 2026. PMID:41829053.
Observational / other LOW evidence YELLOW
Bacteriocin-producing Saccharomyces cerevisiae inhibits bacterial contamination in raw starch-to-ethanol fermentations. ↗

PMID 41819348 ↗

Journal Bioresour Technol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41819348/

Rossouw M et al.. Bacteriocin-producing Saccharomyces cerevisiae inhibits bacterial contamination in raw starch-to-ethanol fermentations.. Bioresour Technol. 2026. PMID:41819348.
Observational / other LOW evidence YELLOW
Alginate alleviates hyperuricemia by modulating the Pediococcus acidilactici LW1-1-butyrate-NLRP3 inflammasome axis. ↗

PMID 41819315 ↗

Journal Int J Biol Macromol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41819315/

Li Y et al.. Alginate alleviates hyperuricemia by modulating the Pediococcus acidilactici LW1-1-butyrate-NLRP3 inflammasome axis.. Int J Biol Macromol. 2026. PMID:41819315.
Observational / other LOW evidence YELLOW
Co-fermentation of Lactiplantibacillus plantarum and Pediococcus acidilactici induces non-thermal gel of tilapia surimi: Quantitative assessment of microbial contribution to gel improvement. ↗

PMID 41799256 ↗

Journal Curr Res Food Sci

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41799256/

Wang C et al.. Co-fermentation of Lactiplantibacillus plantarum and Pediococcus acidilactici induces non-thermal gel of tilapia surimi: Quantitative assessment of microbial contribution to gel improvement.. Curr Res Food Sci. 2026. PMID:41799256.

Q × L × D × S × 10 = 1.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 1.5 / 10

Final GIRI Score for Pediococcus acidilactici. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

LOW RISK 1.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

1.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Pediococcus acidilactici

A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

Pediococcus acidilactici

Safety Profile

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Low classification for Pediococcus acidilactici

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში